27322774|t|The anti-apoptotic PON2 protein is Wnt / β-catenin - regulated and correlates with radiotherapy resistance in OSCC patients
27322774|a|Aberrant Wnt signaling and control of anti-apoptotic mechanisms are pivotal features in different types of cancer to undergo cell death programs. The intracellular human enzyme Paraoxonase-2 (PON2) is known to have anti-apoptotic properties in leukemia and oral squamous cell cancer (OSCC) cells. However, the distinct regulating pathways are poorly understood. First, we present a so far unknown regulation of PON2 protein expression through the Wnt / GSK3β / β-catenin pathway in leukemia and OSCC cells. This was confirmed via in silico analysis, promoter reporter studies and treatment of multiple cell lines (K562, SCC-4, PCI-13) with different Wnt ligands / inhibitors in vitro. Ex vivo analysis of OSCC patients revealed a correlation between PON2 and β-catenin expression in tumor tissue. Higher PON2 expression in OSCC is associated with relapse independently of treatment (e.g. surgery / radio -/ chemotherapy). These results emphasize the clinical impact of the newly described regulation of PON2 through Wnt / GSK3β / β-catenin. More importantly, the study revealed the fundamental finding of an overall Wnt / GSK3β / β-catenin dependent regulation of PON2 in different cancers, which was confirmed by systematic and multimethodological approaches. Thus, the herein presented mechanistic insight contributes to a better understanding of tumor specific escape from cell death strategies and suggests PON2 as a new potential biomarker for therapy resistance or as a prognostic tumor marker.
27322774	4	18	anti-apoptotic	T043	C1512772
27322774	19	31	PON2 protein	T116,T126	C0755726
27322774	35	38	Wnt	T116,T123	C0753137
27322774	41	50	β-catenin	T116,T123	C0105770
27322774	53	62	regulated	T038	C1327622
27322774	67	77	correlates	T080	C1707520
27322774	83	95	radiotherapy	T061	C1522449
27322774	96	106	resistance	T169	C4281815
27322774	110	114	OSCC	UnknownType	C0747035
27322774	115	123	patients	T101	C0030705
27322774	133	146	Wnt signaling	T044	C1520113
27322774	162	176	anti-apoptotic	T043	C1512772
27322774	177	187	mechanisms	T169	C0441712
27322774	231	237	cancer	T191	C0006826
27322774	249	259	cell death	T043	C0007587
27322774	274	287	intracellular	T082	C0178719
27322774	288	293	human	T016	C0086418
27322774	294	300	enzyme	T116,T126	C0014442
27322774	301	314	Paraoxonase-2	T116,T126	C1122373
27322774	316	320	PON2	T116,T126	C1122373
27322774	339	353	anti-apoptotic	T043	C1512772
27322774	368	376	leukemia	T191	C0023418
27322774	381	406	oral squamous cell cancer	UnknownType	C0747035
27322774	408	412	OSCC	UnknownType	C0747035
27322774	414	419	cells	T025	C0007634
27322774	443	453	regulating	T038	C1327622
27322774	454	462	pathways	T077	C1705987
27322774	521	531	regulation	T038	C1327622
27322774	535	547	PON2 protein	T116,T126	C0755726
27322774	548	558	expression	T045	C1171362
27322774	571	574	Wnt	T044	C1520113
27322774	577	582	GSK3β	T116,T126	C0244988
27322774	585	594	β-catenin	T116,T123	C0105770
27322774	595	602	pathway	T044	C1704259
27322774	606	614	leukemia	T191	C0023418
27322774	619	623	OSCC	UnknownType	C0747035
27322774	624	629	cells	T025	C0007634
27322774	657	672	silico analysis	T062	C0936012
27322774	674	699	promoter reporter studies	T062	C0242481
27322774	704	713	treatment	T061	C0087111
27322774	726	736	cell lines	T025	C0007600
27322774	738	742	K562	T025	C1517631
27322774	744	749	SCC-4	T025	C0007634
27322774	751	757	PCI-13	T025	C0007634
27322774	774	777	Wnt	T116,T123	C0753137
27322774	778	785	ligands	T044	C1749457
27322774	788	798	inhibitors	T120	C0243077
27322774	799	807	in vitro	T080	C1533691
27322774	809	816	Ex vivo	T169	C2348480
27322774	817	825	analysis	T062	C0936012
27322774	829	833	OSCC	UnknownType	C0747035
27322774	834	842	patients	T101	C0030705
27322774	854	865	correlation	T080	C1707520
27322774	874	878	PON2	T116,T126	C1122373
27322774	883	892	β-catenin	T116,T123	C0105770
27322774	893	903	expression	T045	C1171362
27322774	907	919	tumor tissue	T024	C0475358
27322774	928	932	PON2	T116,T126	C0755726
27322774	933	943	expression	T045	C1171362
27322774	947	951	OSCC	UnknownType	C0747035
27322774	955	970	associated with	T080	C0332281
27322774	971	978	relapse	T067	C0035020
27322774	996	1005	treatment	T061	C0087111
27322774	1012	1019	surgery	T061	C0543467
27322774	1022	1027	radio	T061	C1522449
27322774	1031	1043	chemotherapy	T061	C3665472
27322774	1074	1082	clinical	T080	C0205210
27322774	1113	1123	regulation	T038	C1327622
27322774	1127	1131	PON2	T116,T126	C1122373
27322774	1140	1143	Wnt	T116,T123	C0753137
27322774	1146	1151	GSK3β	T116,T126	C0244988
27322774	1154	1163	β-catenin	T116,T123	C0105770
27322774	1206	1225	fundamental finding	T033	C0243095
27322774	1240	1243	Wnt	T116,T123	C0753137
27322774	1246	1251	GSK3β	T116,T126	C0244988
27322774	1254	1263	β-catenin	T116,T123	C0105770
27322774	1274	1284	regulation	T038	C1327622
27322774	1288	1292	PON2	T116,T126	C1122373
27322774	1306	1313	cancers	T191	C0006826
27322774	1338	1348	systematic	T169	C0220922
27322774	1353	1372	multimethodological	T170	C0969625
27322774	1473	1478	tumor	T191	C0027651
27322774	1500	1510	cell death	T043	C0007587
27322774	1535	1539	PON2	T116,T126	C1122373
27322774	1549	1558	potential	T080	C3245505
27322774	1559	1568	biomarker	T201	C0005516
27322774	1573	1580	therapy	T061	C0087111
27322774	1581	1591	resistance	T169	C4281815
27322774	1600	1610	prognostic	T170	C0220901
27322774	1611	1623	tumor marker	T123	C0041365